BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bay Area's Versartis, Inc. Secures $55 Million Series E Financing


2/18/2014 7:20:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Versartis Secures $55 Million in Series E Financing

REDWOOD CITY, CA--(Marketwired - Feb 18, 2014) - Versartis, Inc., an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced that it has completed a $55 million Series E financing. Five undisclosed new investors, all of which are leading life science investment firms, joined existing investors Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences in this round. Versartis was founded by Amunix, Inc. and Index Ventures to explore the clinical potential of novel drugs using Amunix's XTEN technology. This financing brings the company's total capital raised to $132 million.

The proceeds from this financing will primarily be used to prepare for an international Phase 3 pediatric GHD trial of VRS-317, the company's proprietary long-acting rhGH for the treatment of GHD. VRS-317 is currently being studied in pediatric GHD patients in a Phase 2a clinical trial to evaluate the 6-month efficacy and safety.

"We are pleased to welcome our new investors to our investor syndicate," said Versartis Chief Executive Officer Jeffery L. Cleland, PhD. "This financing will allow us to further advance the clinical development of our lead compound, VRS-317, which we believe has the potential to be a highly differentiated treatment for pediatric GHD."

About Versartis

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD). The company is currently completing a Phase 2a clinical trial of VRS-317 in children with GHD. Further information on Versartis can be found at www.versartis.com.



Contacts:

Corporate
Joshua Brumm
Chief Financial Officer
650 963-8582

Media
Debra Bannister
Corporate Communications
530 676-7373

Investors
Kimberly Minarovich
Burns McClellan
212 213-0006

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES